ArticleStem cell research & therapy2025
Beclin1 deficiency unlocks cardiac lineage commitment through convergent Wnt and BMP signaling activation.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundEmbryonic stem cell (ESC)-derived cardiomyocytes are a key resource for studying cardiac development and advancing regenerative therapies. Beclin1 (Becn1), a core regulator of autophagy and cardiac morphogenesis, has an undefined role in cardiomyocyte lineage specification. This study aims to investigate the regulatory function of Becn1 during cardiac differentiation from both mouse and human ESCs.
methodsMouse and human ESCs were differentiated into cardiomyocytes through established embryoid body (EB) formation or monolayer differentiation protocols. Stable Becn1 knockdown was achieved using short hairpin RNA (shRNA). Cardiomyocyte differentiation efficiency was evaluated by flow cytometry, immunocytochemistry, and contraction assays. Differentiation cardiomyocyte function was evaluated by sarcomere arrangement, calcium transients, and microelectrode array (MEA). Transcriptomic profiling was conducted by bulk RNA sequencing, and pathway dynamics were analyzed using qPCR and western blotting.
resultsBecn1 expression declined over the course of differentiation. Knockdown of Becn1 significantly enhanced cardiomyocyte yield and promoted earlier onset of contractile activity, accompanied by increased expression of cardiac-specific markers. Mechanistically, Becn1 deficiency elicited a biphasic Wnt signaling response, characterized by early activation during mesodermal induction followed by suppression at later stages of differentiation. This shift was accompanied by sustained BMP pathway activation. Notably, Becn1-deficient ESCs underwent efficient cardiac differentiation in the absence of exogenous VEGF or FGF, with BMP signaling compensating for their omission. These findings were recapitulated in human ESCs, where BECN1 knockdown supported Wnt modulators-independent cardiomyocyte differentiation through coordinated modulation of Wnt and BMP pathways.
conclusionsBecn1 serves as a negative regulator of cardiac lineage commitment by orchestrating stage-specific Wnt/BMP signaling dynamics. Silencing Becn1 enhances cardiomyocyte differentiation and enables growth factor-independent lineage progression. These findings offer a novel approach to improve the efficiency and scalability of stem cell-derived cardiomyocyte production for regenerative applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.